相似文献
1
Urokinase-type plasminogen activator receptor: a beacon of malignancy?
Clin Cancer Res. 2008 Sep 15;14(18):5643-5. doi: 10.1158/1078-0432.CCR-08-1557.
2
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Clin Cancer Res. 2008 Sep 15;14(18):5785-93. doi: 10.1158/1078-0432.CCR-08-0096.
3
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Bosn J Basic Med Sci. 2007 May;7(2):111-6. doi: 10.17305/bjbms.2007.3063.
4
Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma.
Clin Biochem. 2003 Oct;36(7):537-43. doi: 10.1016/s0009-9120(03)00102-4.
5
Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.
Oncol Rep. 2000 Jul-Aug;7(4):879-82. doi: 10.3892/or.7.4.879.
6
Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.
Int J Cancer. 1998 Oct 23;79(5):449-54. doi: 10.1002/(sici)1097-0215(19981023)79:5<449::aid-ijc1>3.0.co;2-0.
7
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Cancer Res. 1998 May 1;58(9):1843-9.
8
High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
Int J Cancer. 2003 Nov 20;107(4):658-65. doi: 10.1002/ijc.11420.
9
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Anticancer Res. 2004 May-Jun;24(3b):1981-5.
10
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Thromb Res. 1998 Jul 1;91(1):23-7. doi: 10.1016/s0049-3848(98)00061-9.
引用本文的文献
1
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.
Neoplasia. 2010 Feb;12(2):161-72. doi: 10.1593/neo.91542.
本文引用的文献
1
Cancer statistics, 2008.
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.
2
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Gynecol Oncol. 2008 Feb;108(2):402-8. doi: 10.1016/j.ygyno.2007.10.017. Epub 2007 Dec 3.
3
The urokinase-system--role of cell proliferation and apoptosis.
Histol Histopathol. 2008 Feb;23(2):227-36. doi: 10.14670/HH-23.227.
4
How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design.
J Clin Epidemiol. 2007 Dec;60(12):1205-19. doi: 10.1016/j.jclinepi.2007.04.020. Epub 2007 Sep 24.
5
Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
Obstet Gynecol. 2007 Jun;109(6):1342-50. doi: 10.1097/01.AOG.0000265207.27755.28.
6
The urokinase plasminogen activator receptor as a gene therapy target for cancer.
Trends Biotechnol. 2007 Jan;25(1):33-9. doi: 10.1016/j.tibtech.2006.10.011. Epub 2006 Nov 7.
7
Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.
Obstet Gynecol. 2006 Jan;107(1):77-85. doi: 10.1097/01.AOG.0000192407.04428.bb.
8
Cancer of the ovary.
N Engl J Med. 2004 Dec 9;351(24):2519-29. doi: 10.1056/NEJMra041842.
9
Progress and challenges in screening for early detection of ovarian cancer.
Mol Cell Proteomics. 2004 Apr;3(4):355-66. doi: 10.1074/mcp.R400006-MCP200. Epub 2004 Feb 5.
10
Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer.
Med Res Rev. 2004 Jan;24(1):13-39. doi: 10.1002/med.10054.
Zotero 插件